tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shandong Boan Biotech Reports Revenue Growth Amid Strategic Shifts

Story Highlights
Shandong Boan Biotech Reports Revenue Growth Amid Strategic Shifts

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) has provided an update.

Shandong Boan Biotechnology Co., Ltd. reported an 8.4% increase in revenue for the first half of 2025, reaching approximately RMB393.4 million, driven by a 15.9% growth in product sales. Despite stable gross profit, the company faced increased selling and distribution expenses, while research and development expenses decreased significantly, reflecting strategic shifts in operational focus.

More about Shandong Boan Biotechnology Company., Limited. Class H

Shandong Boan Biotechnology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the biotechnology industry, focusing on the development and sales of pharmaceutical products such as Boyounuo®, Boyoubei®, and Boluojia®.

Average Trading Volume: 24,575,190

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.17B

See more insights into 6955 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1